
Colorectal Cancer Screening Tests Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Description
Colorectal Cancer Screening Tests Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Summary
GlobalData's Medical Devices sector report, “Colorectal Cancer Screening Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update provides comprehensive information about the Colorectal Cancer Screening Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Colorectal Cancer Screening Tests includes Guaiac Fecal Occult Blood Test (gFOBT) Kits, Immunochemical Fecal Occult Blood Test (iFOBT or FIT) Kits, Fecal DNA Test Kits and Other Colorectal Cancer Screening Tests.
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Colorectal Cancer Screening Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Colorectal Cancer Screening Tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Colorectal Cancer Screening Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
143 Pages
- 1 About GlobalData
- 2 Table of Contents
- 2.1 List of Tables
- 2.2 List of Figures
- 3 Introduction
- 3.1 Colorectal Cancer Screening Tests Overview
- 4 Products under Development
- 4.1 Colorectal Cancer Screening Tests - Pipeline Products by Stage of Development
- 4.2 Colorectal Cancer Screening Tests - Pipeline Products by Segment
- 4.3 Colorectal Cancer Screening Tests - Pipeline Products by Territory
- 4.4 Colorectal Cancer Screening Tests - Pipeline Products by Regulatory Path
- 4.5 Colorectal Cancer Screening Tests - Pipeline Products by Estimated Approval Date
- 4.6 Colorectal Cancer Screening Tests - Ongoing Clinical Trials
- 5 Colorectal Cancer Screening Tests - Pipeline Products under Development by Companies
- 5.1 Colorectal Cancer Screening Tests Companies - Pipeline Products by Stage of Development
- 5.2 Colorectal Cancer Screening Tests – Companies Pipeline Products by Stage of Development
- 6 Colorectal Cancer Screening Tests Companies and Product Overview
- 6.1 Acuamark Diagnostics Inc Company Overview
- 6.1.1 Acuamark Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
- 6.2 Anixa Diagnostics Corporation Company Overview
- 6.2.1 Anixa Diagnostics Corporation Pipeline Products & Ongoing Clinical Trials Overview
- 6.3 Arbele Corp Company Overview
- 6.3.1 Arbele Corp Pipeline Products & Ongoing Clinical Trials Overview
- 6.4 Augusta University Company Overview
- 6.4.1 Augusta University Pipeline Products & Ongoing Clinical Trials Overview
- 6.5 Bar Harbor BioTechnology Inc (Inactive) Company Overview
- 6.5.1 Bar Harbor BioTechnology Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
- 6.6 Beacon Biomedical Inc Company Overview
- 6.6.1 Beacon Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview
- 6.7 Beckman Research Institute Of The City Of Hope Company Overview
- 6.7.1 Beckman Research Institute Of The City Of Hope Pipeline Products & Ongoing Clinical Trials Overview
- 6.8 Beijing Youxun Medical Laboratory Co Ltd Company Overview
- 6.8.1 Beijing Youxun Medical Laboratory Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 6.9 BGI Genomics Co Ltd Company Overview
- 6.9.1 BGI Genomics Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 6.1 Biocartis Group NV Company Overview
- 6.10.1 Biocartis Group NV Pipeline Products & Ongoing Clinical Trials Overview
- 6.11 Biome Diagnostics GmbH Company Overview
- 6.11.1 Biome Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview
- 6.12 Castle Biosciences Inc Company Overview
- 6.12.1 Castle Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
- 6.13 CellMax Life Inc Company Overview
- 6.13.1 CellMax Life Inc Pipeline Products & Ongoing Clinical Trials Overview
- 6.14 Celtic Medical BV Company Overview
- 6.14.1 Celtic Medical BV Pipeline Products & Ongoing Clinical Trials Overview
- 6.15 CRC Bioscreen Company Overview
- 6.15.1 CRC Bioscreen Pipeline Products & Ongoing Clinical Trials Overview
- 6.16 Creative Biosciences (Guangzhou) Co Ltd Company Overview
- 6.16.1 Creative Biosciences (Guangzhou) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 6.17 Curo Biosciences Pvt Ltd Company Overview
- 6.17.1 Curo Biosciences Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 6.18 Diagen Company Overview
- 6.18.1 Diagen Pipeline Products & Ongoing Clinical Trials Overview
- 6.19 DiagNodus Ltd Company Overview
- 6.19.1 DiagNodus Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 6.2 EHang (Suzhou) Biomedical Co Ltd Company Overview
- 6.20.1 EHang (Suzhou) Biomedical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 6.21 Epigenomics Inc Company Overview
- 6.21.1 Epigenomics Inc Pipeline Products & Ongoing Clinical Trials Overview
- 6.22 Exact Sciences Corp Company Overview
- 6.22.1 Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview
- 6.23 Foundation Medicine Inc Company Overview
- 6.23.1 Foundation Medicine Inc Pipeline Products & Ongoing Clinical Trials Overview
- 6.24 G Medical Health and Wellness Company Overview
- 6.24.1 G Medical Health and Wellness Pipeline Products & Ongoing Clinical Trials Overview
- 6.25 Geneoscopy LLC Company Overview
- 6.25.1 Geneoscopy LLC Pipeline Products & Ongoing Clinical Trials Overview
- 6.26 Genetic Technologies Ltd Company Overview
- 6.26.1 Genetic Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 6.27 Genetron Health (Beijing) Co Ltd Company Overview
- 6.27.1 Genetron Health (Beijing) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 6.28 Genoptix Inc (Inactive) Company Overview
- 6.28.1 Genoptix Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
- 6.29 Guardant Health Inc Company Overview
- 6.29.1 Guardant Health Inc Pipeline Products & Ongoing Clinical Trials Overview
- 6.3 Human Metabolome Technologies Inc Company Overview
- 6.30.1 Human Metabolome Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
- 6.31 iCellate Medical AB Company Overview
- 6.31.1 iCellate Medical AB Pipeline Products & Ongoing Clinical Trials Overview
- 6.33 nterpace Biosciences Inc Company Overview
- 6.33.1 Interpace Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
- 6.34 JL Medi Labs Co Ltd Company Overview
- 6.34.1 JL Medi Labs Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 6.35 Mainz Biomed NV Company Overview
- 6.35.1 Mainz Biomed NV Pipeline Products & Ongoing Clinical Trials Overview
- 6.36 mBioSys Pvt Ltd Company Overview
- 6.36.1 mBioSys Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 6.37 Neuome Peptides Pte Ltd Company Overview
- 6.37.1 Neuome Peptides Pte Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 6.38 Oncodiag Company Overview
- 6.38.1 Oncodiag Pipeline Products & Ongoing Clinical Trials Overview
- 6.39 Oncomark Ltd Company Overview
- 6.39.1 Oncomark Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 6.4 Ourotech Ltd Company Overview
- 6.40.1 Ourotech Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 6.41 Prenetics Ltd Company Overview
- 6.41.1 Prenetics Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 6.42 Preora Healthcare Inc Company Overview
- 6.42.1 Preora Healthcare Inc Pipeline Products & Ongoing Clinical Trials Overview
- 6.43 QuantuMDx Group Ltd Company Overview
- 6.43.1 QuantuMDx Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 6.44 Rarity Bioscience AB Company Overview
- 6.44.1 Rarity Bioscience AB Pipeline Products & Ongoing Clinical Trials Overview
- 6.45 Rhythm Biosciences Ltd Company Overview
- 6.45.1 Rhythm Biosciences Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 6.46 Shanghai Singlera Genomics Technologies Co Ltd Company Overview
- 6.46.1 Shanghai Singlera Genomics Technologies Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 6.47 Singlera Genomics Inc Company Overview
- 6.47.1 Singlera Genomics Inc Pipeline Products & Ongoing Clinical Trials Overview
- 6.48 The Chinese University of Hong Kong Company Overview
- 6.48.1 The Chinese University of Hong Kong Pipeline Products & Ongoing Clinical Trials Overview
- 6.49 University of Oxford Company Overview
- 6.49.1 University of Oxford Pipeline Products & Ongoing Clinical Trials Overview
- 6.5 Vastcon Inc Company Overview
- 6.50.1 Vastcon Inc Pipeline Products & Ongoing Clinical Trials Overview
- 6.51 VolitionRX Ltd Company Overview
- 6.51.1 VolitionRX Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 7 Colorectal Cancer Screening Tests- Recent Developments
- 7.1 Nov 17, 2023: Exact Sciences Files Patent Infringement Lawsuit Against Geneoscopy
- 7.2 Nov 15, 2023: Geneoscopy and Labcorp sign deal for colorectal cancer screening test
- 7.3 Nov 14, 2023: Geneoscopy Signs Multi-Year Agreement with Labcorp to Distribute Noninvasive Multi-Target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test
- 7.4 Nov 12, 2023: Guardant Health Launches Shield Blood-Based Screening Test for Colorectal Cancer In South Korea
- 7.5 Nov 09, 2023: Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test
- 7.6 Nov 07, 2023: Mainz Biomed to Showcase ColoAlert at Leading Global Healthcare Event, MEDICA
- 7.7 Nov 02, 2023: 2San Receives CLIA Approval For One Step Immunochemical Fecal Occult Blood Test (iFOB)
- 7.8 Nov 02, 2023: Zydus and Guardant Health to Jointly Promote the GUARDANT360 Portfolio of Nextgeneration Genomic Tests for Advanced Solid Cancers in India and Nepal
- 7.9 Oct 19, 2023: Invitae Appoints Dr. David Sholehvar as Chief Operating Officer
- 7.1 Oct 18, 2023: Mainz Biomed Presents Groundbreaking Results of Colofuture Study
- 7.11 Oct 11, 2023: Mainz Biomed to Showcase ColoAlert at UEG Week 2023 in Copenhagen, Denmark
- 7.12 Oct 09, 2023: Exact Sciences to Present Late-Breaking Data from Pivotal BLUE-C Study on Next-Generation Cologuard at ACG 2023
- 7.13 Oct 04, 2023: Mainz Biomed Announces Live Launch of ColoAlert with Bioclinica in Romania
- 7.14 Sep 27, 2023: Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology
- 7.15 Sep 25, 2023: Invitae Announces Appointment of Finance Veteran Ana Schrank as CFO
- 7.16 Sep 13, 2023: Mainz Biomed looks to expand cancer identification list for ColoAlert
- 7.17 Sep 05, 2023: Mainz Biomed Announces Strategic Partnership With ÄRztliches Labor Dr. Buhlmann, Expanding Footprint in German Market
- 7.18 Aug 29, 2023: Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference
- 7.19 Aug 28, 2023: Invitae Hires Industry Veteran Robert Guigley as Chief Commercial Officer
- 7.2 Aug 22, 2023: Mainz Biomed Announces Live Launch of ColoAlert with testDNA Laboratory in Poland
- 7.21 Aug 14, 2023: Invitae Announces Selection of Finance Executive Robert Dickey as Interim CFO
- 7.22 Aug 03, 2023: CVS Health to Begin Nationwide In-Store Sales of Biomerica’s EZ Detect Colorectal Disease Screening Test
- 7.23 Aug 01, 2023: Mainz Biomed Announces Live Launch of ColoAlert with Marylebone Laboratory in the United Kingdom
- 7.24 Jul 06, 2023: iCellate Medical Discontinues Direct-To-Consumer Sales of Its GeneMate service
- 7.25 Jul 03, 2023: Rhythm Establishes UK subsidiary for Market Entry
- 7.26 Jun 29, 2023: Mainz Biomed Secures up to $50M in New Funding
- 7.27 Jun 28, 2023: Mainz Biomed to Attend ESMO World Congress on Gastrointestinal Cancer 2023 in Barcelona, Spain
- 7.28 Jun 20, 2023: Mainz Biomed Expands into Romania Through Partnership with Bioclinica
- 7.29 Jun 08, 2023: iCellate Medical Secures 20 MSEK in New Funding
- 7.3 Jun 06, 2023: Abstract & Poster Highlighting Positive Clinical Results For Colostat Poster Presentation at ASCO Annual Meeting
- 7.31 May 31, 2023: Mainz Biomed expands commercial footprint into Poland
- 7.32 May 25, 2023: Invitae Announces CFO Transition and Selection of Veteran Finance Executive Christine Gorjanc as Interim CFO
- 7.33 May 24, 2023: Mainz Biomed processes first patients from colorectal cancer Screening campaign through its corporate health portal in partnership with Zoeller-Kipper
- 7.34 May 24, 2023: Executes a UK strategic partnership with LINK Medical Solutions
- 7.35 May 18, 2023: CK Life Sciences Int'l (Holdings) announces poll results at annual general meeting
- 7.36 May 17, 2023: Exact Sciences awards grants to 18 organizations focused on increasing colorectal cancer screenings
- 7.37 May 17, 2023: UKCA mark granted for ColoSTAT
- 7.38 May 09, 2023: Invitae reports Q1 2023 financial results
- 7.39 May 04, 2023: BCAL Diagnostics opens new laboratory in sydney as it accelerates development of its breast cancer blood screening tool
- 7.4 May 03, 2023: Mainz Biomed announces addition of Eurofins GeLaMed to its growing network of lab partners
- 7.41 May 01, 2023: Mainz Biomed to participate in Digestive Disease Week 2023
- 7.42 Apr 26, 2023: Mainz Biomed announces partnership with the Instituto de Microecologia to expand ColoAlert commercialization in Spain and Portugal
- 7.43 Apr 26, 2023: Invitae to Announce First Quarter 2023 Financial Results on Tuesday, May 9, 2023
- 7.44 Apr 24, 2023: Salix Partners with the Colorectal Cancer Alliance on community screening program
- 7.45 Apr 21, 2023: Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer
- 7.46 Apr 20, 2023: Bescreened blood-based colorectal cancer test available at any lab test now locations across the country
- 7.47 Apr 16, 2023: DiaCarta announces five abstracts accepted for presentation at AACR Annual Meeting 2023
- 7.48 Apr 06, 2023: ColoSTAT abstract accepted for presentation at 2023 ASCO Annual Meeting
- 7.49 Apr 04, 2023: Mainz Biomed expands corporate health program for ColoAlert with the addition of Three new companies in Germany
- 7.5 Apr 03, 2023: Labcorp Expands Access to Colorectal Cancer Screening Through Partnership with the Conference of National Black Churches
- 7.51 Mar 29, 2023: BGI Genomics partners with Zentya to launch fecal DNA test for colorectal cancer in Slovakia
- 7.52 Mar 29, 2023: Mainz Biomed reports positive results from feasibility study evaluating its portfolio of novel mRNA biomarkers for early detection of advanced colorectal adenomas
- 7.53 Mar 23, 2023: $3.3 million grant to IU researchers aims to increase colorectal cancer screening in rural Indiana
- 7.54 Mar 21, 2023: Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence
- 7.55 Mar 21, 2023: QuikRead go iFOBT is a quantitative feacal test for detecting excess gastrointestinal bleeding
- 7.56 Mar 15, 2023: BeScreened blood-based colorectal cancer test provides affordable early detection and without the mess
- 7.57 Mar 15, 2023: Mainz Biomed announces partnership with Labor Staber to expand ColoAlert commercialization in Germany
- 7.58 Mar 13, 2023: Guardant Health seeks US FDA premarket approval for CRC screening test
- 7.59 Mar 06, 2023: Rhythm Biosciences : Update to TGA Submission for ColoSTAT Test-Kit
- 7.6 Mar 02, 2023: Smiths Detection and GRASP innovations to collaborate on technology integration
- 7.61 Feb 15, 2023: Guardant Health initiates new study to examine the impact of Shield blood test to increase screening compliance for colorectal cancer
- 7.62 Feb 15, 2023: Mainz Biomed expands European commercial footprint and enters markets in Spain and UK
- 7.63 Feb 15, 2023: Rhythm maintains ISO certification
- 7.64 Feb 07, 2023: BGI COLOTECT 3.0 demonstrates higher colorectal cancer detection sensitivity than FIT
- 7.65 Jan 31, 2023: Guardant360 CDx gets FDA approval as companion diagnostic for ORSERDU
- 7.66 Jan 24, 2023: Geneoscopy submits premarket approval application to U.S. Food and Drug Administration for its noninvasive Colorectal Cancer RNA Biomarker Screening Test
- 7.67 Jan 18, 2023: Mainz Biomed launches corporate health program in Germany for ColoAlert
- 7.68 Jan 09, 2023: Foundation Medicine and Natera announce the launch of FoundationOneTracker personalized circulating tumor DNA monitoring assay for investigational use and early access clinical use
- 7.69 Dec 20, 2022: Mainz Biomed enrolls first patient in eAArly DETECT study evaluating integration of novel mRNA biomarkers into ColoAlert
- 7.7 Dec 15, 2022: Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer
- 7.71 Dec 14, 2022: Epigenomics releases performance data on Next Generation test
- 7.72 Dec 08, 2022: Biomerica receives KFDA and Ministry of Health approval for Colorectal Screening and Breast Screening Tests in Saudi Arabia and UAE
- 7.73 Dec 06, 2022: Mainz Biomed announces IRB approval and initiation of US pivotal FDA clinical study
- 7.74 Nov 29, 2022: BGI preparing to launch improved non-invasive colorectal cancer screening test, COLOTECT 3.0
- 8 Appendix
- 8.1 Methodology
- 8.2 About GlobalData
- 8.3 Contact Us
- 8.4 Disclaimer
- 2.1 List of Tables
- Table 1: Colorectal Cancer Screening Tests - Pipeline Products by Stage of Development
- Table 2: Colorectal Cancer Screening Tests - Pipeline Products by Segment
- Table 3: Colorectal Cancer Screening Tests - Pipeline Products by Territory
- Table 4: Colorectal Cancer Screening Tests - Pipeline Products by Regulatory Path
- Table 5: Colorectal Cancer Screening Tests - Pipeline Products by Estimated Approval Date
- Table 6: Colorectal Cancer Screening Tests - Ongoing Clinical Trials
- Table 7: Colorectal Cancer Screening Tests Companies - Pipeline Products by Stage of Development
- Table 8: Colorectal Cancer Screening Tests – Companies Pipeline Products by Stage of Development
- Table 9: Acuamark Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
- Table 10: Eagle i5 - Product Status
- Table 11: Eagle i5 - Product Description
- Table 12: Anixa Diagnostics Corporation Pipeline Products & Ongoing Clinical Trials Overview
- Table 13: Cchek - Colon Cancer Screening Test - Product Status
- Table 14: Cchek - Colon Cancer Screening Test - Product Description
- Table 15: Anixa Diagnostics Corporation - Ongoing Clinical Trials Overview
- Table 16: Cchek - Colon Cancer Screening Test - The Coupling of MDSCs with a Computational Analytic Method to Detect Solid Tumors
- Table 17: Arbele Corp Pipeline Products & Ongoing Clinical Trials Overview
- Table 18: CDH17 - Blood Test - Product Status
- Table 19: CDH17 - Blood Test - Product Description
- Table 20: Augusta University Pipeline Products & Ongoing Clinical Trials Overview
- Table 21: Folate Receptor Biomarker Test - Cervical Cancer - Product Status
- Table 22: Folate Receptor Biomarker Test - Cervical Cancer - Product Description
- Table 23: Bar Harbor BioTechnology Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
- Table 24: Genetic Diagnostic Test - Colorectal Cancer - Product Status
- Table 25: Genetic Diagnostic Test - Colorectal Cancer - Product Description
- Table 26: Beacon Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview
- Table 27: ColoRT - Product Status
- Table 28: ColoRT - Product Description
- Table 29: Beckman Research Institute Of The City Of Hope Pipeline Products & Ongoing Clinical Trials Overview
- Table 30: Biomarker Test - Colorectal Cancer - Product Status
- Table 31: Biomarker Test - Colorectal Cancer - Product Description
- Table 32: Beijing Youxun Medical Laboratory Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
- Table 33: Youxu Colorectal Cancer IVD Test - Product Status
- Table 34: Youxu Colorectal Cancer IVD Test - Product Description
- Table 35: BGI Genomics Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
- Table 36: COLOTECT 3.0 - Product Status
- Table 37: COLOTECT 3.0 - Product Description
- Table 38: Biocartis Group NV Pipeline Products & Ongoing Clinical Trials Overview
- Table 39: Idylla - KRAS-NRAS-BRAF Test - Product Status
- Table 40: Idylla - KRAS-NRAS-BRAF Test - Product Description
- Table 41: Biome Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview
- Table 42: BiomeCRC - Product Status
- Table 43: BiomeCRC - Product Description
- Table 44: Castle Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
- Table 45: DecisionDx - Rectal Cancer - Product Status
- Table 46: DecisionDx - Rectal Cancer - Product Description
- Table 47: CellMax Life Inc Pipeline Products & Ongoing Clinical Trials Overview
- Table 48: FirstSight Blood Test - Colorectal Cancer - Product Status
- Table 49: FirstSight Blood Test - Colorectal Cancer - Product Description
- Table 50: Celtic Medical BV Pipeline Products & Ongoing Clinical Trials Overview
- Table 51: Celtic Panel - Colorectal Cancer - Product Status
- Table 52: Celtic Panel - Colorectal Cancer - Product Description
- Table 53: CRC Bioscreen Pipeline Products & Ongoing Clinical Trials Overview
- Table 54: Immunochemical Test - Colorectal Cancer - Product Status
- Table 55: Immunochemical Test - Colorectal Cancer - Product Description
- Table 56: Creative Biosciences (Guangzhou) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
- Table 57: Colosafe 2.0 - Product Status
- Table 58: Colosafe 2.0 - Product Description
- Table 59: Curo Biosciences Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
- Table 60: ERLYSIGN Kit - Colorectal Cancer - Product Status
- Table 61: ERLYSIGN Kit - Colorectal Cancer - Product Description
- Table 62: Diagen Pipeline Products & Ongoing Clinical Trials Overview
- Table 63: Colon Cancer Diagnostic Kit - Product Status
- Table 64: Colon Cancer Diagnostic Kit - Product Description
- Table 65: DiagNodus Ltd Pipeline Products & Ongoing Clinical Trials Overview
- Table 66: Diagnostic Test - Colorectal Cancer - Product Status(DiagNodus Ltd)
- Table 67: Diagnostic Test - Colorectal Cancer - Product Description(DiagNodus Ltd)
- Table 68: EHang (Suzhou) Biomedical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
- Table 69: Blood-Based Exosome Assay - Colorectal Cancer - Product Status
- Table 70: Blood-Based Exosome Assay - Colorectal Cancer - Product Description
- Table 71: Epigenomics Inc Pipeline Products & Ongoing Clinical Trials Overview
- Table 72: Next-Generation Colorectal Cancer Test - Product Status
- Table 73: Next-Generation Colorectal Cancer Test - Product Description
- Table 74: Epigenomics Inc - Ongoing Clinical Trials Overview
- Table 75: Next-Generation Colorectal Cancer Test - Prospective, Multi-center Observational Study for the Clinical Validation of the Next Generation Test for Blood-based Screening of Colorectal Cancer
- Table 76: Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview
- Table 77: Circulating Tumor DNA Test - Colorectal Cancer - Product Status
- Table 78: Circulating Tumor DNA Test - Colorectal Cancer - Product Description
- Table 79: Exact Sciences Corp - Ongoing Clinical Trials Overview
- Table 80: Circulating Tumor DNA Test - Colorectal Cancer - Clinical Validation Study of Circulating Tumor DNA Test to Detect Minimal Residual Disease in Patients with Colorectal Cancer: CORRECT-MRD II
- Table 81: Circulating Tumor DNA Test - Colorectal Cancer - CORRECT-MRD II: Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using a Circulating Tumor DNA Assay to Detect Minimal Residual Disease
- Table 82: Foundation Medicine Inc Pipeline Products & Ongoing Clinical Trials Overview
- Table 83: ctDNA Monitoring Assay - Product Status
- Table 84: ctDNA Monitoring Assay - Product Description
- Table 85: G Medical Health and Wellness Pipeline Products & Ongoing Clinical Trials Overview
- Table 86: Colon Cancer-Screening Test - Product Status
- Table 87: Colon Cancer-Screening Test - Product Description
- Table 88: Geneoscopy LLC Pipeline Products & Ongoing Clinical Trials Overview
- Table 89: Multi-Target Stool RNA (Mt-sRNA) Biomarker Panel - Product Status
- Table 90: Multi-Target Stool RNA (Mt-sRNA) Biomarker Panel - Product Description
- Table 91: Geneoscopy LLC - Ongoing Clinical Trials Overview
- Table 92: Multi-Target Stool RNA (Mt-sRNA) Biomarker Panel - Clinical Validation of the ColonoSight Test: A Multi-target Stool RNA (Mt-sRNA) Assay for Colorectal Neoplasia Screening in Average-risk Individuals Aged More Than 45 Years Old
- Table 93: Genetic Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview
- Table 94: Genetic Test - Colorectal Cancer - Product Status
- Table 95: Genetic Test - Colorectal Cancer - Product Description
- Table 96: Genetron Health (Beijing) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
- Table 97: CRC Early Screening Assay - Product Status
- Table 98: CRC Early Screening Assay - Product Description
- Table 99: Genoptix Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
- Table 100: Epidermal Growth Factor Receptor Assay - Colon Cancer - Product Status
- Table 101: Epidermal Growth Factor Receptor Assay - Colon Cancer - Product Description
- Table 102: Guardant Health Inc Pipeline Products & Ongoing Clinical Trials Overview 5
- Table 103: Guardant Shield IVD-CRC Test - Product Status 5
- Table 104: Guardant Shield IVD-CRC Test - Product Description 5
- Table 105: Guardant360 Liquid Biopsy Test - Product Status
- Table 106: Guardant360 Liquid Biopsy Test - Product Description
- Table 107: LUNAR-2 Assay - Product Status
- Table 108: LUNAR-2 Assay - Product Description
- Table 109: Guardant Health Inc - Ongoing Clinical Trials Overview
- Table 110: LUNAR-2 Assay - Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
- Table 111: Guardant Shield IVD-CRC Test - Blood-Based Colorectal Cancer (CRC) Screening Implementation Into Clinical Practice in the Outpatient Clinical Settings in the Appalachian Highlands
- Table 112: Guardant Shield IVD-CRC Test - The Ohio State University Guardant Shield Colorectal Cancer Screening Project
- Table 113: Guardant Shield IVD-CRC Test - Understanding Patient Preference on Colorectal Cancer Screening Options
- Table 114: Human Metabolome Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
- Table 115: Biomarker Based Assay - Colorectal Cancer - Product Status
- Table 116: Biomarker Based Assay - Colorectal Cancer - Product Description
- Table 117: iCellate Medical AB Pipeline Products & Ongoing Clinical Trials Overview
- Table 118: CellMate - Colorectal Cancer - Product Status
- Table 119: CellMate - Colorectal Cancer - Product Description
- Table 120: Interpace Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
- Table 121: PathFinderTG - Colon (Supernatant) - Product Status
- Table 122: PathFinderTG - Colon (Supernatant) - Product Description
- Table 123: JL Medi Labs Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
- Table 124: Diagnostic Test - Colorectal Cancer - Product Status(JL Medi Labs Co Ltd)
- Table 125: Diagnostic Test - Colorectal Cancer - Product Description(JL Medi Labs Co Ltd)
- Table 126: Mainz Biomed NV Pipeline Products & Ongoing Clinical Trials Overview
- Table 127: Next Generation AA/CRC Screening Test - Product Status
- Table 128: Next Generation AA/CRC Screening Test - Product Description
- Table 129: Mainz Biomed NV - Ongoing Clinical Trials Overview
- Table 130: Next Generation AA/CRC Screening Test - A Study to Evaluate the Integration of a Portfolio of Novel Gene Expression (mRNA) Biomarkers into ColoAlert 5
- Table 131: Next Generation AA/CRC Screening Test - Clinical Performance of the Mainz Biomed Colorectal Cancer Screening Test for the Detection of Colorectal Cancer and Advanced Adenoma in an Average Risk Population 5
- Table 132: Next Generation AA/CRC Screening Test - Validity and Diagnostic Performance of an Optimized Multi-target Stool Nucleic Acid Test Combined with FIT (ColoAlert 3.0) For Early Detection of Colorectal Cancer and Advanced Precancerous Lesions in Colon 5
- Table 133: mBioSys Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 6
- Table 134: Detection Kit - Colorectal Cancer - Product Status 6
- Table 135: Detection Kit - Colorectal Cancer - Product Description 6
- Table 136: Neuome Peptides Pte Ltd Pipeline Products & Ongoing Clinical Trials Overview
- Table 137: Diagnostic Assay - Colorectal Cancer - Product Status
- Table 138: Diagnostic Assay - Colorectal Cancer - Product Description
- Table 139: Oncodiag Pipeline Products & Ongoing Clinical Trials Overview
- Table 140: Colodiag - Product Status
- Table 141: Colodiag - Product Description
- Table 142: Oncomark Ltd Pipeline Products & Ongoing Clinical Trials Overview
- Table 143: OncoMasTR - Colorectal Cancer - Product Status
- Table 144: OncoMasTR - Colorectal Cancer - Product Description
- Table 145: Ourotech Ltd Pipeline Products & Ongoing Clinical Trials Overview
- Table 146: Organ-On-A-Chip Device - Colorectal Cancer - Product Status
- Table 147: Organ-On-A-Chip Device - Colorectal Cancer - Product Description
- Table 148: Prenetics Ltd Pipeline Products & Ongoing Clinical Trials Overview
- Table 149: ColoClear - Product Status
- Table 150: ColoClear - Product Description
- Table 151: Preora Healthcare Inc Pipeline Products & Ongoing Clinical Trials Overview
- Table 152: Cancer Risk Stratification Test - Colorectal Cancer - Product Status
- Table 153: Cancer Risk Stratification Test - Colorectal Cancer - Product Description
- Table 154: QuantuMDx Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
- Table 155: Q-POC - HPV Assay - Product Status
- Table 156: Q-POC - HPV Assay - Product Description
- Table 157: Rarity Bioscience AB Pipeline Products & Ongoing Clinical Trials Overview
- Table 158: Colorectal Cancer Panel - Product Status
- Table 159: Colorectal Cancer Panel - Product Description
- Table 160: Rhythm Biosciences Ltd Pipeline Products & Ongoing Clinical Trials Overview 5
- Table 161: ColoSTAT - Product Status 5
- Table 162: ColoSTAT - Product Description 5
- Table 163: Shanghai Singlera Genomics Technologies Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 6
- Table 164: ColonAiQ - Product Status 6
- Table 165: ColonAiQ - Product Description 6
- Table 166: Singlera Genomics Inc Pipeline Products & Ongoing Clinical Trials Overview 7
- Table 167: ColonES Assay - Product Status 7
- Table 168: ColonES Assay - Product Description 7
- Table 169: The Chinese University of Hong Kong Pipeline Products & Ongoing Clinical Trials Overview
- Table 170: Colorectal Cancer Screening Tool - Product Status
- Table 171: Colorectal Cancer Screening Tool - Product Description
- Table 172: University of Oxford Pipeline Products & Ongoing Clinical Trials Overview
- Table 173: Companion Diagnostic Assay - Colorectal Cancer - Product Status
- Table 174: Companion Diagnostic Assay - Colorectal Cancer - Product Description
- Table 175: Vastcon Inc Pipeline Products & Ongoing Clinical Trials Overview
- Table 176: Screening Test - Colorectal Cancer - Product Status
- Table 177: Screening Test - Colorectal Cancer - Product Description
- Table 178: VolitionRX Ltd Pipeline Products & Ongoing Clinical Trials Overview
- Table 179: Nu.Q CRC Screening Test - Product Status
- Table 180: Nu.Q CRC Screening Test - Product Description
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.